Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia

Core Insights - Tyra Biosciences has initiated the BEACH301 Phase 2 clinical study for dabogratinib, the only oral FGFR3-selective inhibitor in development for achondroplasia, marking a significant milestone in the treatment of this condition [1][2][3] Company Overview - Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines targeting FGFR biology, utilizing its in-house SNÅP platform for drug design [9] - Dabogratinib is the lead candidate from Tyra's pipeline, designed to be a first-in-class oral FGFR3-selective inhibitor, with ongoing clinical trials for both pediatric achondroplasia and cancer [7][9] Clinical Study Details - The BEACH301 study will evaluate dabogratinib in children aged 3 to 10 with achondroplasia, enrolling treatment-naïve participants and those who have received prior therapies [4][5] - The study aims to assess safety, tolerability, and growth velocity changes, with a focus on improving the quality of life for children with achondroplasia [5][6] Market Context - Achondroplasia affects approximately 1 in 15,000 to 40,000 children, with around 250,000 individuals impacted globally, highlighting a significant unmet medical need [2][6] - The FGFR3 G380R mutation is responsible for about 99% of achondroplasia cases, indicating a targeted therapeutic approach could be beneficial [2][6]